McKesson Corporation (MCK)

Investment Committee Summary

Investment Thesis

At $874 on 25 August 2026, the market values McKesson near 20 times forward earnings — a multiple that treats the distributor as a low-growth, low-margin toll on drug volumes rather than as a specialty-services franchise. The engine agrees on the character of the earnings stream: thin-margin and volume-driven, with a base case pairing modest revenue growth with an operating margin near 1.6% on an enormous revenue base. It disagrees on what that stream is currently worth. Triangulated fair value of $769 is a gap of -12% to spot, the probability-weighted expected value is $781 and the twelve-month target is $753; the shares are fairly valued against the weighted anchors, which is what produces the HOLD. Peer anchors frame the range on both sides rather than pointing one way, and the discounted-cash-flow anchor sits among them, so there is no margin of safety in either direction — only a price that has run ahead of the weighted arithmetic. The single most damaging risk is structural: if payers and manufacturers extract margin from the distribution channel, the razor-thin margin and the toll multiple compress together, and the bear target sits below the 52-week low.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($874) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The most probable bear mechanism is not a crash but slow channel disintermediation. McKesson earns an operating margin near 1.6% on each revenue dollar, so it has almost no cushion. If manufacturers widen direct-to-payer and direct-to-pharmacy arrangements, and generic deflation outruns specialty mix gains, that margin drifts lower still on flat-to-declining volumes. Thin economics make earnings extraordinarily sensitive: a fractional loss of margin removes a large share of the profit, because the denominator is revenue and the numerator is a rounding error against it. The market would then re-rate the stream from a toll multiple toward a structurally impaired one, so earnings and multiple compress in the same direction rather than offsetting. That combination, not a single bad quarter, is what carries the structural target below the 52-week low, and net debt of ~$4.6B constrains how much of the gap can be bought back.

Key Debate

Gross Margin explains 81% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 19.6× consensus forward EPS, vs the house DCF terminal 14.0×, and a peer median 15.7×. The house DCF sits 7% below spot, so the market is pricing in more than the house case — roughly 0.8pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Channel Disintermediation / Reimbursement' downside ($367) to a 'Bull — Re-Rate' bull case ($1,197); the probability-weighted blend (PWEV $781) is -11% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — free cash flow net of SBC is $5.72B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Channel Disintermediation / Reimbursement (20%, $367). Structural impairment — channel disintermediation / reimbursement: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Volume / Generic-Deflation Pressure (17%, $680). Cyclical downturn — pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation weakens for 1–2 years before normalising.
• Base — Drug-Volume + Specialty Growth (35%, $834). Mid-cycle — normalised pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation; disciplined capital allocation; steady returns.
• Growth — Specialty / Services Expansion (20%, $1,023). Upside — specialty + services expansion lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $1,197). Upside tail — sustained tight conditions or a structural re-rate on specialty + services expansion.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $654 and 33% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (81% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.0%, 14.0x terminal FCF multiple → $810. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $778; the peer-median forward P/E is 15.7x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 20% of the median — moderate (healthy method disagreement — read the blend with care).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Drug Distribution multiple (AI re-rating) (base 17.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 17.0× (simple median 15.7×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $634–$998, centre $796 (-9% vs spot); spot sits at the 66th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $1,197.

Company Overview & Business Model

McKesson Corporation — HEALTHCARE · MEDICAL DISTRIBUTION. McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.

How it makes money.

Edge. Wide moat. Authored moat rationale withheld pending re-authoring.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2026-03-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue.

Competitive Moat

Moat sources:

• FACT: US pharma distribution is a ~90%-share oligopoly (MCK/ABC/CAH); scale density drives the lowest cost-per-package
• FACT: specialty/oncology (US Oncology Network, provider services) is a higher-margin, stickier adjacency built on physician relationships
• INFERENCE: manufacturer contracts and DEA-controlled logistics create high barriers to new entrants
• ABSENCE: core distribution is a low-margin, price-taking business — the moat is cost-scale, not pricing power over payers

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q3): management +0.24 vs analyst floor +0.22 → delta +0.02 (n=25 mgmt / 9 Q&A; 0th pctile across the S&P book, z -2.4).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 1341 articles): avg ticker sentiment +0.22 (bullish 29% / bearish 2%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-15 (~52d) — GLP-1 distribution-volume / margin update as branded-drug mix shifts (authored)
• 2027-02-04 (~164d) — Specialty / oncology-platform M&A or partnership milestone (Core Ventures / provider-services build-out) (authored)

Forecast Track Record

• EPS surprise: beat 100% of the last 8 quarters; average surprise +3.2%.
• Prior-forecast backtest (12 snapshots, 2026-06-27→2026-08-20): directional hit-rate 25%; mean predicted -10.1% vs realised +4.3%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

6 catalysts in the next 90 days (of 15 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 0 caution rules triggered of 5 evaluable (1 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• US Pharmaceutical segment operating margin < 0.0135 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Adjusted operating profit growth, US Pharmaceutical segment < 0.03 (2 consecutive prints). Base and volume-pressure scenarios diverge on whether segment profit compounds mid-single-digits. Two prints below the base/bear midpoint would move probability weight toward the cyclical-pressure state.
• Consolidated revenue growth < 0.03 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Fiscal-year adjusted EPS guidance revision < 0.0 (single event). A downward cut to the full-year adjusted EPS range would directly contradict the earnings compounding embedded in the base target and would validate the earnings leg of the disintermediation scenario.
• Trailing-twelve-month operating cash flow < 5.0 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $874; 52-week range $634–$998; engine rating HOLD; house target $753 (-14%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $769 (-12% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

65.0/100 (confidence band 51.4–78.5), 76th percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 64.8 → 64.8 → 65.0 → 64.3 → 64.3 → 62.4 → 65.2 → 65.2.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $781.28.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.00, vs QQQ -0.08 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Long Stock. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• no directional edge and options are cheap — options add little; hold the stock
• Direction neutral from the overlay conviction/rating (read-only input).
• IV/RV at the 20th percentile of the cross-section → low vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 75th percentile of its own month-end history (decile 8). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +3.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Long Stock was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +3.9pp): 25-DTE 27% · 88-DTE 31% · 389-DTE 31%

No live-chain Long Stock was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: . IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 26.9% (subdued regime) · expected move ±5.5% (2026-09-18) · put/call OI 0.59 · ATM Δ 0.55 / Θ -0.53 / ν 0.90. Direction: NEUTRAL (implied return -12.0% to triangulated fair value $768.99).

Covered Call (if held) (Income / neutral) — Short 930 C · 2026-09-18 · premium $5.45 · yield 0.6% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 800 P / Long 740 P · 2026-10-16 · net $4.4 · net entry $795.60 · yield 0.5% · RoR 8.0% · max loss $55.60 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 790 P / Short 960 C · 2027-02-19 · net $8.9 · floor -10.0% · cap +10.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -11% vs spot
• Monte Carlo median implies -25% vs spot
• DCF fair value implies -7% vs spot — but this is terminal-value sensitive (exit-multiple $810 vs Gordon $1,012, 25% apart), so it carries less weight
• Bear case (Structural — Channel Disintermediation / Reimbursement) downside is -58% vs spot
• Net: the valuation anchor itself sits 12.0% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 1% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.0% · Σ PV(FCF) $28B + PV(terminal) $72B = EV $100B; − net debt $4.6B → equity $96B ÷ diluted shares $0.12B = $810/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $1,012/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 44% vs WACC 8.0% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $778 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (2566.0); Revenue CAGR ±3pp (218.0); Terminal × ±15% (183.0); WACC ±1pp (70.0); Capex intensity ±15% (18.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.0%, terminal multiple 14×, FY+5 revenue $496B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.